Modifi Bio News Today

The firm is developing a pipeline of therapeutics directed at cancer tumors that have lost expression of the DNA repair protein MGMT.

Modifi Biosciences announced today that the journal Science has published a critical study validating the company's novel oncology platform based on new classes of molecules that exploit tumor-associated DNA repair defects through direct cancer cell DNA modification.

Yale Spinout Modifi Bio announces seed funding...